Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  330 results for ""ANTINEOPLASTIC agents""

Your Filters

Filter by : Subject Geographic : asia
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

A review on paying for advanced cancer therapeutics: hard truths and realities in Asia.

  • Authors : Wong EYT; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Lim JFY

Subjects: Neoplasms*/Neoplasms*/Neoplasms*/drug therapy ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use; Humans

  • Source: Chinese clinical oncology [Chin Clin Oncol] 2023 Aug; Vol. 12 (4), pp. 40. Date of Electronic Publication: 2023 Jul 31.Publisher: AME Publishing Company Country of Publication: China NLM ID: 101608375 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region.

  • Authors : So TH; Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU), Hong Kong.; Sharma S

Subjects: Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/drug therapy ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/adverse effects ; Kidney Neoplasms*/Kidney Neoplasms*/Kidney Neoplasms*/drug therapyClear-cell metastatic renal cell carcinoma

  • Source: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2023 Jul-Dec; Vol. 23 (8), pp. 853-863. Date of Electronic Publication: 2023 Aug 07.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.

  • Authors : Ren X; Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Yan C

Subjects: Cyclin-Dependent Kinase 4*/Cyclin-Dependent Kinase 4*/Cyclin-Dependent Kinase 4*/antagonists & inhibitors ; Hematologic Diseases*/Hematologic Diseases*/Hematologic Diseases*/chemically induced ; Hematologic Diseases*/Hematologic Diseases*/Hematologic Diseases*/epidemiology

  • Source: International journal of immunopathology and pharmacology [Int J Immunopathol Pharmacol] 2022 Jan-Dec; Vol. 36, pp. 3946320221145520.Publisher: Sage Publications Country of Publication: England NLM ID: 8911335 Publication Model: Print Cited Medium: Internet ISSN: 2058-7384

Record details

Read More Add to Saved list
×
Academic Journal

Herbals and Plants in the Treatment of Pancreatic Cancer: A Systematic Review of Experimental and Clinical Studies.

  • Authors : Triantafillidis JK; GI Department, Metropolitan General Hospital, 15562 Holargos, Greece.; Hellenic Society of Gastrointestinal Oncology, 354, Iera Odos Street, Haidari, 12461 Athens, Greece.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/pathology

  • Source: Nutrients [Nutrients] 2022 Jan 30; Vol. 14 (3). Date of Electronic Publication: 2022 Jan 30.Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.

  • Authors : Chuah C; Singapore General Hospital, Duke-NUS Medical School, 20 College Road, Singapore, 169856, Singapore. .; Koh LP

Subjects: Aniline Compounds/Aniline Compounds/Aniline Compounds/*therapeutic use ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Imatinib Mesylate/Imatinib Mesylate/Imatinib Mesylate/*therapeutic use

  • Source: International journal of hematology [Int J Hematol] 2021 Jul; Vol. 114 (1), pp. 65-78. Date of Electronic Publication: 2021 Apr 13.Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.

  • Authors : Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; George S

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Gastrointestinal Neoplasms/Gastrointestinal Neoplasms/Gastrointestinal Neoplasms/*drug therapy ; Gastrointestinal Stromal Tumors/Gastrointestinal Stromal Tumors/Gastrointestinal Stromal Tumors/*drug therapy

  • Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Oct 01; Vol. 39 (28), pp. 3128-3139. Date of Electronic Publication: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.

  • Authors : Hata T; International Trial Management Section, Research Management Division, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.; Nakamura K

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Drug Approval/Drug Approval/Drug Approval/*legislation & jurisprudence ; Drugs, Investigational/Drugs, Investigational/Drugs, Investigational/*pharmacology

  • Source: Clinical and translational science [Clin Transl Sci] 2021 May; Vol. 14 (3), pp. 1015-1025. Date of Electronic Publication: 2021 Mar 01.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.

  • Authors : Byun JM; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Yoon SS

Subjects: Drug Resistance, Neoplasm*; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use

  • Source: Anticancer research [Anticancer Res] 2019 Sep; Vol. 39 (9), pp. 5165-5170.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

  • Authors : Kato K; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Electronic address: .; Cho BC

Subjects: Drug Resistance, Neoplasm*; Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*administration & dosage ; Docetaxel/Docetaxel/Docetaxel/*administration & dosage

  • Source: The Lancet. Oncology [Lancet Oncol] 2019 Nov; Vol. 20 (11), pp. 1506-1517. Date of Electronic Publication: 2019 Sep 30.Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

  • Authors : Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.; Even C

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*administration & dosage ; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*administration & dosage ; Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*administration & dosage

  • Source: JAMA oncology [JAMA Oncol] 2019 Feb 01; Vol. 5 (2), pp. 195-203.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  330 results for ""ANTINEOPLASTIC agents""